Draulio Silveira
Clinical Researcher in Psychedelic Psychiatry
Papers
Trials
Key Impact
Notable for conducting early clinical and phenomenological studies of psychedelic-assisted therapies in Brazil, including MDMA-assisted psychotherapy for severe PTSD, ibogaine for drug dependence, and investigations of ayahuasca use in adolescents.
Background & Research
Draulio da Silveira is a Brazilian clinical researcher focused on empirical and qualitative investigations of psychedelic compounds in the context of psychiatry and addiction medicine. His work spans pilot clinical trials and phenomenological analyses that examine both therapeutic outcomes and the subjective experiences elicited by substances such as MDMA, ibogaine and ayahuasca. He has contributed to early open-label clinical research assessing MDMA-assisted psychotherapy for survivors of sexual abuse with severe post-traumatic stress disorder, and to detailed qualitative and neuropsychological assessments of ayahuasca use in adolescent populations.
Da Silveira's research blends clinical outcome measurement with qualitative and phenomenological methods to elucidate mechanisms of change, safety profiles and lived experience under psychedelic treatments. His publications include a pilot MDMA-assisted psychotherapy study in Brazil, a phenomenological analysis of ibogaine experiences in the context of drug-dependence treatment, and a series of psychiatric, neuropsychological and qualitative assessments of ayahuasca in adolescents — collectively advancing understanding of therapeutic potential, developmental considerations and harms minimisation in psychedelic research within Brazilian clinical settings.